The minimally effective dose of sucrose for procedural pain relief in neonates: a randomized controlled trial

• DOI: 10.1186/s12887-018-1026-x
• Publication Date: 2018-02-23T08:28:09Z
• Authors: Bonnie Stevens; Janet Yamada; Marsha Campbell-Yeo; Sharyn Gibbins; Denise Harrison; Kimberley Dionne; Anna Taddio; Carol McNair; Andrew Willan; Marilyn Ballantyne; Kimberley Widger; Souraya Sidani; Carole Estabrooks; Anne Synnes; Janet Squires; Charles Victor; Shirine Riahi
• Keywords: Adverse event; NICU; Male; Sucrose; PIPP-R; 610; Pain; Administration, Oral; Pain, Procedural; Pediatrics; RJ1-570; 618; 03 medical and health sciences; 0302 clinical medicine; 616; Humans; Single-Blind Method; Prospective Studies; Pain Measurement; Analgesics; Dose-Response Relationship, Drug; Infant, Newborn; Preterm infants; Neonates; 3. Good health; Treatment Outcome; Female; Analgesia; Heel lance; Research Article

Orally administered sucrose is effective and safe in reducing pain intensity during single, tissue-damaging procedures neonates, commonly recommended neonatal guidelines. However, there wide variability doses examined research, more than a 20-fold variation across care settings. The aim of this study was to determine the minimally dose 24% for hospitalized neonates undergoing single skin-breaking heel lance procedure. A total 245 from 4 Canadian tertiary intensive units (NICUs), born between 24 42 weeks gestational age (GA), were prospectively randomized receive one three sucrose, plus non-nutritive sucking/pacifier, 2 min before routine lance: 0.1 ml (Group 1; n = 81), 0.5 2; or 1.0 3; 83). primary outcome measured at 30 60 s following lance, using Premature Infant Pain Profile-Revised (PIPP-R). secondary incidence adverse events. Analysis covariance models, adjusting GA site group differences intervention groups. There no difference mean PIPP-R scores treatment groups (P .97) .93); however, not fully eliminated 5 reported events among 5/245 (2.0%) with significant proportion by .62). All resolved spontaneously without medical intervention. required treat associated ml. Further evaluation regarding sustained effectiveness repeated painful warranted. ClinicalTrials.gov : NCT02134873. Date: May 5, 2014 (retrospectively registered).